{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:45:19Z","timestamp":1795031119994,"version":"4.10.2"},"reference-count":20,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The 2019 American Society of Hematology (ASH) guidelines for immune thrombocytopenia (ITP) included recommendations on the management of adults (recommendations 1-9) and children (recommendations 10-21) with primary ITP . We describe here the results of a review of the 2019 guidelines by a working group of experts requested by ASH to inform decision-making about the need for and timing of a guideline revision. An updated Medline and Embase search applied the same search terms as in the 2019 ASH guidelines, limited to systematic reviews and clinical trials, from May 2017 to July 2022. There were 193 studies identified, 102 underwent abstract reviews, and 54 full reviews. Each study was assessed based on relevance to the previous recommendation with regard to the population, prioritized outcomes, new outcomes, and study design. Reviewers assessed if the data would change the strength or the directionality of the existing recommendation or merit development of a new recommendation. Based on this review, the ASH Committee on Quality endorsed a focused update on second-line management for adults with ITP. In addition, there will be continued annual monitoring and reviewing of the 2019 ASH guidelines on ITP in full to evaluate when there is sufficient new evidence to warrant additional revisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012541","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T16:40:18Z","timestamp":1712940018000},"page":"3578-3582","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":64,"title":["The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-6107","authenticated-orcid":false,"given":"Cindy E.","family":"Neunert","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0943-8853","authenticated-orcid":false,"given":"Donald M.","family":"Arnold","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-0449","authenticated-orcid":false,"given":"Rachael F.","family":"Grace","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Dana-Farber\/Boston Children\u2019s Medical Center and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7387-7028","authenticated-orcid":false,"given":"Thomas","family":"Kuhne","sequence":"additional","affiliation":[{"name":"4Division of Oncology\/Hematology, Pediatric Oncology\/Hematology, University Children\u2019s Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7340-475X","authenticated-orcid":false,"given":"Keith R.","family":"McCrae","sequence":"additional","affiliation":[{"name":"5Taussig Cancer Institute and Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0794-5851","authenticated-orcid":false,"given":"Deirdra R.","family":"Terrell","sequence":"additional","affiliation":[{"name":"6Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"23","key":"2024070915211177500_bib1","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"16","key":"2024070915211177500_bib2","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2024070915211177500_bib3","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1055\/s-0037-1604168","article-title":"Efficacy of dexamethasone for acute primary immune thrombocytopenia compared to prednisolone: a systematic review and meta-analysis","volume":"1","author":"Arai","year":"2017","journal-title":"TH Open"},{"key":"2024070915211177500_bib4","first-page":"88","article-title":"Evaluation of treatment plan by three-period pulses of high-dose dexamethasone among patients with primary immune thrombocytopenia on platelet count response and adverse events: a randomized clinical trial","volume":"25","author":"Sadeghi","year":"2020","journal-title":"J\u00a0Res Med Sci"},{"key":"2024070915211177500_bib5","doi-asserted-by":"crossref","first-page":"656792","DOI":"10.3389\/fmed.2021.656792","article-title":"The efficacy of high-dose dexamethasone vs. other treatments for newly diagnosed immune thrombocytopenia: a meta-analysis","volume":"8","author":"Xiao","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"2024070915211177500_bib6","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3026(21)00240-4","article-title":"All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"8","author":"Huang","year":"2021","journal-title":"Lancet Haematol"},{"issue":"12","key":"2024070915211177500_bib7","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/ajh.25989","article-title":"High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: a prospective, multicenter, randomized trial","volume":"95","author":"Yu","year":"2020","journal-title":"Am J Hematol"},{"issue":"10","key":"2024070915211177500_bib8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024070915211177500_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2018-02-830844","article-title":"Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial","volume":"132","author":"Heitink-Polle","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2024070915211177500_bib10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"2024070915211177500_bib11","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program","volume":"94","author":"Bussel","year":"2019","journal-title":"Am J Hematol"},{"key":"2024070915211177500_bib12","doi-asserted-by":"crossref","first-page":"20406207211010875","DOI":"10.1177\/20406207211010875","article-title":"Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib","volume":"12","author":"Cooper","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"2024070915211177500_bib13","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.1002\/ajh.24698","article-title":"Evaluation of the efficiency of hydroxychloroquine in treating children with immune thrombocytopenia (ITP)","volume":"92","author":"Roche","year":"2017","journal-title":"Am J Hematol"},{"key":"2024070915211177500_bib14","doi-asserted-by":"crossref","first-page":"106895","DOI":"10.1016\/j.intimp.2020.106895","article-title":"Sirolimus versus cyclosporine for the treatment of pediatric chronic immune thrombocytopenia: a randomized blinded trial","volume":"88","author":"Mousavi-Hasanzadeh","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"2024070915211177500_bib15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00277-022-04784-0","article-title":"Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: a multiple-treatments network meta-analysis","volume":"101","author":"Zhou","year":"2022","journal-title":"Ann Hematol"},{"issue":"37","key":"2024070915211177500_bib16","doi-asserted-by":"crossref","first-page":"e7534","DOI":"10.1097\/MD.0000000000007534","article-title":"Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura: a PRISMA-compliant systematic review and meta-analysis of 28 studies","volume":"96","author":"Weber","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2024070915211177500_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jclinepi.2020.10.016","article-title":"Using GRADE evidence to decision frameworks to choose from multiple interventions","volume":"130","author":"Piggott","year":"2021","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"17","key":"2024070915211177500_bib18","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2024070915211177500_bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"issue":"15","key":"2024070915211177500_bib20","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3578\/2233885\/blooda_adv-2023-012541-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3578\/2233885\/blooda_adv-2023-012541-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T12:31:09Z","timestamp":1720528269000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/13\/3578\/515729\/The-2022-review-of-the-2019-American-Society-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":20,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012541","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]}}}